替吉奥联合奥沙利铂新辅助化疗治疗胃癌的临床效果

The Clinical Effect of S-1 Combined with Oxaliplatin Neoadjuvant Chemotherapy for Gastric Cancer

目的:探讨替吉奥联合奥沙利铂新辅助化疗治疗胃癌的临床效果。方法:选择笔者所在医院2014年5月-2016年5月收治的110例胃癌患者,按照随机数字法将其分为两组。对照组患者给予奥沙利铂+亚叶酸钙+5-氟尿嘧啶治疗,观察组患者接受替吉奥联合奥沙利铂新辅助化疗。观察两组患者疾病控制情况,并就两组患者治疗过程中不良反应发生情况展开分析,同时采用生活质量简表(SF-36)对治疗前后两组患者生活质量变化情况进行评分。结果:观察组患者疾病控制率83.64%,与对照组的81.82%比较,差异无统计学意义(P>0.05);但观察组患者不良反应发生率12.73%,低于对照组的25.45%,差异有统计学意义(P<0.05)。两组患者治疗后SF-36评分显著优于治疗前,且观察组显著优于对照组,差异有统计学意义(P<0.05)。结论:替吉奥联合奥沙利铂新辅助化疗治疗胃癌的效果较好,且不良反应较少,患者耐受性好,能显著提高患者生活质量,值得推广。

Objective： To investigate the clinical effect of S-l combined with Oxa]iplatin neoadjuvant chemotherapy for gastric cancer.Method： From May 2014 to May 2016, 110 cases of gastric cancer patients who admitted to our hospital were selected and divided into two groups according to the random number method.The control group was treated with Oxaliplatin, Calcium Folinate and 5-Fluorouracil treatment, the observation group patients received neoadjuvant chemotherapy with S-1 combined with Oxaliplatin.The disease control and the adverse reactions of the two groups of patients in the process of occurrence were analyzed, and the quality of life scale（SF-36） score of two groups before and after treatment changes in life quality was compared.Result： The disease control rate was 83.64% and 81.82% in the control group and the observation ,g,g,g,g^up, there was no significant difference in two groups（P〉0.05）, but the occurrence of adverse reactions of patients 12.73% in the observation group was obviously lower than 25.45% in the control group, the difference was statistically significant（P〈0.05）. After treatment, the SF-36 score of the two groups was significantly better than before treatment, and the observation group was significantly better than the control group, the difference was statistically significant（P〈0.05）.Conclusion： The effect of S-1 combined with Oxaliplatin neoadjuvant chemotherapy for gastric cancer treatment is good, and less adverse reactions, with good tolerance, can significantly improve the quality of life of patients, worthy of promotion.